Moderna says Covid vaccine 96% effective in 12-to-17 year olds | World News - Hindustan Times
close_game
close_game

Moderna says Covid vaccine 96% effective in 12-to-17 year olds

Bloomberg |
May 06, 2021 05:28 PM IST

US government support of a waiver of patent protections for Covid-19 vaccines at the World Trade Organization could weigh on Moderna’s shares.

Moderna Inc. said studies of its Covid vaccine in teenagers showed that it was 96% effective and raised its product sales projections for the year as it reported its first-ever profitable quarter.

The company raised its product sales projection for 2021 to $19.2 billion from $18.4 billion.(REUTERS)
The company raised its product sales projection for 2021 to $19.2 billion from $18.4 billion.(REUTERS)
  • Total revenue for the quarter was $1.94 billion, Moderna said, versus the average expectation of $2.22 billion. Moderna reported earnings of $2.84 a share; analysts had expected adjusted earnings of $2.34 a share.
  • The company raised its product sales projection for 2021 to $19.2 billion from $18.4 billion.

Key Insights

Unlock exclusive access to the latest news on India's general elections, only on the HT App. Download Now! Download Now!
  • Initial results from the company’s study of its Covid-19 vaccine in 12-to-17 year old adolescents showed that the vaccine was 96% effective with no serious safety problems, the company said.
  • Moderna is racing to bolster production capacity to help inoculate the world from Covid-19 and keep viral variants at bay. It recently announced investments in U.S. plants and overseas contractors that will raise supply of its Covid vaccine to as many as 3 billion doses next year. The final count depends on the mix of primary two-dose vaccine and booster shots that use less vaccine material.
  • On Wednesday, Moderna released results of preliminary human trials showing that two types of booster shots helped bolster immune responses against variants that surfaced in South Africa and Brazil.
  • U.S. government support of a waiver of patent protections for Covid-19 vaccines at the World Trade Organization could weigh on Moderna’s shares.

Market Performance

  • Moderna fell 6.7% in trading before U.S. markets opened. The shares have gained 56% since the year began through Wednesday’s close.


Tell us what your First Vote will stand for in a short video & get a chance to be featured on HT’s social media handles. Click here to know more!

Get Current Updates on India News, Elections 2024, Lok sabha election 2024 voting live , Karnataka election 2024 live in Bengaluru , Election 2024 Date along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Monday, May 27, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On